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Summary Palpable breast cysts with an apocrine epithelial lining (type 1) are reported to be associated with a
higher risk of developing breast cancer. The composition of breast cyst fluid (BCF) might include those factors
involved in this increased risk. In this study peptidase activities that were active against the substrate ['251I]met-
enkephalin-Arg-Phe were detected in BCF. The products were identified by reversed phase high-performance
liquid chromatography (HPLC) as ['25I]Tyr-Gly-Gly and [251I]Met-enkephalin. This proteolysis was not
inhibited by PCMB, pepstatin A, leupeptin or aprotinin but was by EDTA, showing that the activity was due
to metalloproteases. The production of ['25I]Try-Gly-Gly was inhibited by phosphoramidon and thiorphan,
whereas that of ['25I]met-enkephalin was inhibited by captopril and Bothrops jararaca peptide, indicating that
these activities are enkephalinase and angiotensin-converting enzyme (ACE) respectively. A fluorometric assay
for ACE demonstrated that ACE levels are significantly higher in type 2 BCF than in type 1 BCF (30.8 vs
6.1 nmol hr- 10 pl-', P<0.001). As the increased risk of cancer is linked to type 1 cysts it is possible that
higher levels of peptidase in type 2 BCF reflect a protective environment in the breast in which mitogenic
peptide growth factors are neutralised by proteolysis.
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Gross cystic disease (GCD) of the breast is a common benign
breast disorder that can affect up to 7% of women in the
West. Several studies have linked GCD to a subsequent
increased risk of developing breast cancer (Haagensen, 1971;
Bodian, 1990; Ciatto et al., 1990; Bundred et al., 1991;
Naldoni et al., 1992; Bodian, 1993; Leis, 1993; Caraci et al.,
1994). In these studies gross cysts were defined as palpable
cysts, larger than 1 cm, from which fluid could be aspirated.
There has been some controversy in this field as a link
between cystic disease and subsequent increased cancer risk
was not detected in two large retrospective histological
studies (Page et al., 1978; Dupont and Page, 1985). However
these histological studies did not separate the cysts into type
1 and type 2 and, more importantly, used a very inclusive
definition of a cyst as being larger than 3 mm, thus including
many cysts from which it would not be possible to obtain
BCF. It seems likely that the outcome of studies on BCF
differ from histological studies because they are examining
different populations of cysts and it may be that only large
aspiratable cysts are linked to an increased risk of
subsequently developing breast cancer (Bundred et al.,
1991). However, some increased breast cancer risk has
recently been reported (Dupont et al., 1993) linked to breast
cysts, even using the 3-mm-diameter definition of a cyst.
Breast cysts can be classified according to their epithelial
lining and the composition of the breast cyst fluid (BCF) that
is aspirated from them. Type 1 cysts are lined with apocrine
epithelium and contain BCF with a high level of potassium
ions and a low level of sodium ions whereas type 2 cysts have
a flattened epithelial lining and contain BCF with low
potassium and high sodium ion concentrations. The
increased risk of breast cancer is associated with type 1
cysts (Dixon et al., 1985; Bodian, 1993; Leis, 1993; Caraci et
al., 1994; Angeli et al., 1994).
This association between cysts and cancer risk has led to a
large number of studies on the composition of BCF. As
tumours do not develop in the cyst lining at a greater
frequency than in other breast tissue (Bodian, 1993) it seems
that the components of BCF are not directly tumour
promoting. However BCF components are derived from
breast tissue by transudative and secretory mechanisms and it
has been suggested (e.g. Miller et al., 1992; Reed et al., 1944)
that BCF can provide an insight into the environment within
the breast. As increased cancer risk is associated with type 1
rather than type 2 BCF then a comparison of the two could
indicate the environment in which breast tumours develop,
even though they are likely to develop at sites remote from
the cyst. Factors identified in this way can then be
investigated with other experimental approaches.
Breast cyst fluid contains a variety of hormones and
growth factors, which it has been suggested may be
implicated in the increased risk of developing breast cancer,
including peptide growth factors such as gastrin-releasing
peptide (Weber et al., 1989; Lai et al., 1990a), epidermal
growth factor (Hamed et al., 1990; Lai et al. 1990b) and
transforming growth factor (TGF)-j (Ness et al., 1993). It
has also been reported that the opiate peptide beta endorphin
is present in BCF (Schurz et al., 1991; Schon et al., 1993).
This led us to attempt to measure another opiate peptide
(Met-enkephalin-Arg-Phe) in BCF and in the course of that
study we observed that proteolytic activities that cleaved this
peptide were present in BCF (Frame and Parish, 1992). It has
been suggested that peptidases might modulate cell growth,
including the growth of carcinomas, through the inactivation
of peptide growth factors (Kenny et al., 1989). As the
presence of these peptidases in BCF may well reflect
peptidase levels within the breast they are of interest as a
possible factor in regulating breast cancer. In this paper we
describe the characterisation of the peptidase activities in
BCF that cleave Met-enkephalin-Arg-Phe.
Materials and methods
Breast cyst fluid was obtained by needle aspiration of breast
cysts from women attending the breast clinic at St Mary's
Hospital, London, with their informed consent. Samples were
centrifuged at 1500 g for 10 min to remove cellular debris
and the supernatant was stored at -20°C until assay.
Electrolytes were measured by flame spectrophotometry.
Cyst fluids were classified as type 1 if they had a Na+/K+
Correspondence: DC Parish
Received 9 August 1995; revised 11 March 1996; accepted 25 March
1996ACE and enkephalinass in BCF
KL Frame et al
ratio below 3 and as type 2 if the ratio was greater than or
equal to 3. Peptides were iodinated by the chloramine T
method.
Incubations were performed in a total volume of 200 pl of
0.1 M sodium phosphate, pH 7.4 with 10000 c.p.m. of
[1251]met-enkephalin-Arg-Phe, 20 Mg of unlabelled met-enke-
phalin-Arg-Phe and 25 ,ul of breast cyst fluid. When indicated
in the results protease inhibitors and metal ions were added.
Each set of incubations included a control that contained no
breast cyst fluid. The samples were incubated for 18 h at 4°C
and then a 50 ,ul aliquot of each incubate was mixed with
50 MI of 20% acetonitrile, 0.1% TFA and centrifuged for
10 min in a microfuge. Samples were then applied to an LKB
PepSep reverse-phase high-performance liquid chromatogra-
phy (HPLC) column and eluted at 1 ml min-' with buffer A
(20% acetonitrile, 0.1% TFA) combined with a gradient of
buffer B (80% acetonitrile, 0.1% TFA) from 0% to 50% in
30 min. Fractions (1 ml) were collected and radiolabelled
peptides detected in a gamma counter.
The assay for angiotensin-converting enzyme was adapted
from Friedland and Silverstein (1976). Aliquots of 10 ,ul of
sample were incubated in a total volume of 250 ,l of 0.5 M
potassium phosphate, 1.5 M sodium chloride 0.5 mM zinc
chloride, pH 8.3, with 5 mM final concentration of hippuryl-
His-Leu at 37°C for 1 h. The reaction was terminated with
1.45 ml of 0.28 M sodium hydroxide and the product then
incubated with 100,l of 2% o-phthaldialdehyde for 15 min
at room temperature and this reaction terminated with 200 pl
of 3.0 M hydrochloric acid. Fluorescence was measured with
excitation at 360 nm and emission at 500 nm. A standard
curve of His-Leu (from 0 to 10 nmol/tube of His-Leu) was
incubated under these conditions for each assay. Samples that
contained activity exceeding the upper limits of the standard
curve were diluted 1:10 or 1:100 and reassayed. All samples
and standards were assayed in duplicate and BCF samples
were also treated at 100°C for 5 min and assayed in
duplicate. The interassay coefficient of variation was 3.8%,
determined by including aliquots of the same BCF in assays
over a period of 3 months. This also demonstrated that the
activity was stable on storage despite freezing and thawing.
Peptides, substrates, rabbit lung ACE and inhibitors were
obtained from Sigma. Bothrops jararaca peptide is available
as ACE inhibitor peptide from Sigma and is a proline-rich
peptide (Ondetti et al., 1971).
Enzyme activity in the two groups was compared using the
Mann-Whitney test and correlation coefficients were
calculated using Spearman's rank correlation method.
Results
[125I]Met-enkephalin-Arg-Phe eluted as a single radioactive
peak on reverse-phase HPLC (Figure la), however after
incubation of this peptide with a type 1 breast cyst fluid two
further peaks were observed that eluted in the positions of
the [1251I]met-enkephalin and the [1251I]Tyr-Gly-Gly markers
(Figure lb). These same two peaks and no others were
observed to be generated by the five different BCFs that were
examined. The BCFs that had the greatest degree of
proteolysis also had the greatest apparent immunoreactivity
in a met-enkephalin-Arg-Phe radioimmunoassay (Frame and
Parish, 1992). A series of radiolabelled and unlabelled
peptides were chromatographed with this gradient and
another gradient (0-10% buffer B in 10min followed by
10-60% in 40 min, data not shown) and these products of
incubation with BCF did not chromatograph in the elution
position of Tyr, Tyr-Gly, [1251]Tyr-Gly-Gly-Phe or ['25I]Arg-
Tyr-Gly-Gly-Phe-Met.
To determine which proteases were involved in this
proteolysis a type 1 BCF was incubated with a variety of
inhibitors. Whereas inhibitors of thiol, aspartyl and serine
proteases were relatively ineffective, EDTA, an inhibitor of
metalloproteases, produced a marked inhibition (Table 1).
Therefore inhibitors of known metalloproteases that might
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Figure 1 HPLC separation of (a) ['251]met-enkephalin-Arg-Phe
and (b) [125I]Met-enkephalin-Arg-Phe incubated with BCF. The
elution positions of [I251]Tyr-Gly-Gly(l) [125I]met-enkephalin(2)
and ['25I]met-enkephalin-Arg-Phe(3) were determined separately
and are indicated.
cleave this peptide were examined and it was found that ACE
inhibitors (captopril and Bothrops jararaca peptide) inhibited
the formation of the peak eluting in the position of [125I]met-
enkephalin (Table I and Figure 2a) and inhibitors of
enkephalinase (phosphoramidon and thiorphan) inhibited
the formation of the [125I]Tyr-Gly-Gly peak (Table I and
Figure 3a). BCF in the presence of thiorphan produced the
same peaks as are produced by commercially available ACE
(Figure 3a and b), whereas incubation with inhibitors of both
peptidases together prevented all proteolysis (Table I andFigure 2b). The inhibition by EDTA was reversed most
effectively by Zn2+ rather than other divalent cations (Table
I).
Separation of incubation products on HPLC was very
useful for the initial identification of these enzyme activities;
however, it is too time-consuming to form a routine assay.
Therefore an assay for angiotensin-converting enzyme
(Friedland and Silverstein, 1976) was employed, in which
BCF samples were incubated with hippuryl-His-Leu, gen-
erating His-Leu, which is then converted to a fluorescent
product. The generation of this product was inhibited by
captopril and EDTA and the action of EDTA was reversed
by zinc ions (Table II). A low but detectable background
level of fluorescence was present in BCF even when the fluid
was boiled to inactivate enzymes. This was determined for
each sample and subtracted from the fluorescence measured
in the assay to arrive at the level of fluorescence due to
enzyme activity. ACE activity was observed in all BCFs and
is plotted as a scattergram against Na/K ratio (Figure 4a).
The same data are plotted with the BCFs classified as type 1
or type 2 by Na/K ratio (Figure 4b) and the ACE levels in
type 2 BCF are significantly higher than in type 1 (mean of
30.8 nmol h-110 jll-' compared with 6.1, P<0.001). Mea-
surements of both serum and breast cyst fluid ACE levels
were obtained from some patients (Figure 5) and were
inversely correlated (rs= -0.65, P<0.05).
Discussion
The initial observation that the apparent immunoreactive
met-enkephalin-Arg-Phe detected in BCF did not dilute in
parallel with the standard curve led us to examine possible
explanations. When radiolabelled peptide incubated under
the same conditions was chromatographed on reverse-phase
HPLC it was found that the peptide was cleaved into smaller
fragments (Frame and Parish, 1992). This would interfere
with the assay as the antibody used does not recognise
smaller peptides and the effect of reducing the labelled
peptide available to the antibody would be indistinguishable
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from displacement of labelled peptide from the antibody by
met-enkephalin-Arg-Phe in the sample, and hence would be
measured as an apparent immunoreactivity. Those BCFs with
the highest protease activity also had the highest apparent
immunoreactivity.
The identity of the peptides produced can be determined
by comparing their elution positions with those of synthetic
standards. Radiolabelled standards were prepared as
iodinated peptides might elute in slightly different positions
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Table I Inhibition of BCF proteolysis of met-enkephalin-Arg-Phe
Inhibition of Inhibition of
Inhibitor Tyr-Gly-Gly met-enkephalin
production(%)a production(%)a
Protease inhibitors
DTT(lmM) 33 0
PCMB (lmM) 0 0
Pepstatin A (1 pM) 0 14.9
Leupeptin (100,UM) 0 19.3
Aprotinin (10pM) 19.1 1.5
Metallopeptidase
inhibitors
Bestatin (10pM) 0 19.6
Bjararaca peptide (2.27pM) 50 10
Captopril (100pM) 34.3 84.3
Phosphoramidon (250 uM) 74 0
Thiorphan (100pgM) 69 0
Thiorphan +captopril 47 80.3
Thiorphan+Bjararaca peptide 91 95.8
EDTA (1 mM) 79.2 100
Divalent cation replacement
EDTA +Zn2+ (1.5mM) 12.2 Stimulated
EDTA+Co2+ (1.5mM) 67.4 57.8
EDTA+Cu2+ (1.5mM) 72.9 23.6
EDTA+Mg2+ (1.5mM 73.4 92.6
EDTA+Ca + (1.5mM) 58.3 73.8
aPer cent inhibition is expressed as the reduction in the amount of
radioactivity inaypeak compared with an incubation ofthe same BCF
sample with [12 I]met-enkephalin-Arg-Phe and no inhibitor. The
products are identified by their elution in the same position as
labelled standards.
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Figure 2 HPLC separation of (a) [125I]met-enkephalin-Arg-Phe
incubated with BCF and captopril and (b) [125I]met-enkephalin-
Arg-Phe incubated with BCF, captopril and thiorphan (con-
centrations as in Table I).ACE and enkephalinase in BCF $0 KL Frame et al
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Table II Effect of inhibitors on proteolysis of hippuryl-His-Leu by
BCF
Inhibitor Inhibition of His-Leu production (%)a
Captopril (100tiM) 100
Thiorphan (100gM) 37.3
EDTA (10 uM) 98.9
EDTA (IO OM)+ 28.5
zinc chloride (10 uM)
aInhibition is the amount by which activity is reduced compared
with a BCF sample incubated at the same time.
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Figure 3 HPLC separation of (a) [125I]met-enkephalin-Arg-Phe
incubated with BCF and thiorphan and (b) [125I]met-enkephalin-
Arg-Phe incubated with 2.5mU of rabbit lung ACE.
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Figure 4 ACE activity measured by fluorimetric assay. (a)
Plotted as a scattergram against Na/K ratio. (b) With BCF fluid
classified as type 1 (Na/K<3) or type 2 (Na/K > 3). Horizontal
bars indicate the means.
from the unlabelled peptides. Met-enkephalin-Arg-Phe has
the sequence Tyr-Gly-Gly-Phe-Met-Arg-Phe and is only
iodinated on the N-terminal tyrosine residue. As this method
will only detect the radiolabelled products of peptide cleavage
the only possible identities for the products are the iodinated
forms of Tyr, Tyr-Gly, Tyr-Gly-Gly, Tyr-Gly-Gly-Phe, Tyr-
Gly-Gly-Phe-Met or Tyr-Gly-Gly-Phe-Met-Arg (as the last
peptide is not commercially available we substituted Arg-Tyr-
Gly-Gly-Phe-Met, which we would expect to have an
identical elution position in these systems). The product
peaks detected corresponded to Tyr-Gly-Gly and to met-
enkephalin and not to any of the other possible peptide
products. In order to characterise the activities a variety of
protease inhibitors were added to the incubate and EDTA
was found to be the most effective. As this is a
metalloprotease inhibitor a variety of more specific inhibitors
were investigated and of these enkephalinase and ACE
inhibitors were found to be the most effective.
S
0
0
0
0 @0.
*.-
_ ,AA _ . __ ,
Alk n _-ACE and enkephalinase in BCF
KL Frame et a!
811
ACE activity was also found in the serum of patients with
BCF (Figure 5), at similar levels to those measured in normal
subjects with a hippuryl-His-Leu fluorimetric assay (Hayakari
et al., 1984). If ACE activity in breast cyst fluid were derived
from the circulation (e.g. by a filtration process) then serum
and BCF levels would correspond. However serum levels of
ACE activity and the ACE levels in BCF showed an inverse
correlation, which suggests that ACE in BCF is not derived
by uptake from the circulation and probably originates from
a local source.
0
* 0
0
0
1° ° O°1
0 10 20 30
ACE activity in serum (nmol h-1
Figure 5 Scattergram of ACE activity measured
in both serum and BCF of patients with type 1 (I
(0) cysts.
Enkephalinase (EC 24.11)
This study provides strong evidence that
activity is present in BCF. Firstly, the activity
peptide Tyr-Gly-Gly, which is the norma
enkephalin cleavage by enkephalinase and sec
tion of this product is inhibited by EDTA a]
enkephalinase inhibitors phosphoramidon and
may be that the inhibition is not complete bec;
produces Tyr-Gly-Gly, see below). These I
characteristic of enkephalinase. Enkephalir
previously been reported in breast cyst fluid,
known to occur on myoepithelial cells of the I
breast where it was first identified as CALLA
al., 1986), an antigen that is now known to I
enkephalinase (Shipp et al., 1989).
Angiotensin-converting enzyme
Several lines of evidence show that ACE is pr
Firstly the product of incubation of ['25I]MEF
enkephalin, which is the expected product
dipeptidyl carboxypeptidase. It was demo
commercially available ACE produces this F
same substrate (Figure 3b), confirming a p
(Kase et al., 1986). As ACE is a dipeptidyl car
it might be expected to continue proteolysi
['25I]met-enkephalin to ['25I]Tyr-Gly-Gly. In
amount of this product can be seen in Figur
has also been reported previously (Kase et a
may explain why thiorphan, an inhibitor of
did not completely inhibit the production of
Gly. The met-enkephalin-producing activity wz
captopril and Bothrops jararaca peptide, whiz
ACE inhibitors.
Enzymatic activity was also detected in E
ACE-specific substrate hippuryl-His-Leu a:
inhibited by captopril and EDTA. Therefore
substrates are cleaved in the manner that wou
for ACE and cleavage of both is inhibited by A
which can be taken as strong evidence that this a
Other proteases in BCF
Proteolytic activities directed against larger proteins have
previously been identified in BCF. For example a chymo-
tryptic activity capable of cleaving ['4C]albumin occurs in
both type 1 and type 2 BCF (Kesner et al., 1988) whereas
cathepsin D is also found in BCF and is significantly higher
in type 1 cyst fluids (Scambia et al., 1991; Sanchez et al.,
1992), although this is largely in the form of procathepsin D
and therefore is probably not proteolytically active (Sanchez
et al., 1992). It has been suggested (Kesner et al., 1988) that
O the function of proteases in BCF is to produce poorly
diffusible peptide fragments, which would increase the
40 50 osmotic pressure within the cyst and hence lead to an
/10 gl) increase in the cyst volume. However the demonstration of
ACE and enkephalinase in BCF suggests another role, the
simultaneously regulation of levels ofgrowth-promoting peptides and growth
0) and type 2 factors. Other metalloproteases, such as the matrix metallo-
proteinases (collagenases, stromelysins, etc.) are known to be
present in breast tumours and cell lines and to promote
metastasis (Parish, 1994), however their principal mode of
action is thought to be proteolysis of the extracellular matrix
rather than of growth factors.
enkephalinase Practical implications generates the
tl product of The presence of peptidases in BCF has implications for the
ondly, genera- measurement of the concentrations of peptides in BCF.
nd the specific Firstly there is the possibility that these peptidases may
I thiorphan (it continue to act after the collection of BCF. It would be useful
ause ACE also to introduce suitable inhibitors into BCF at the time of
properties are collection. As ACE and enkephalinase are metallopeptidases
iase has not it would therefore be advantageous to collect BCF into
however it is EDTA-containing tubes when peptide levels are to be assayed
human and rat in these samples. Secondly these activities may interfere with
.(Gusterson et some assays, such as the radioimmunoassay (RIA) for met-
be identical to enkephalin-Arg-Phe. Thirdly it is likely that these peptidases
are active in BCF in vivo, in which case the levels of peptides
measured in BCF may not be a reflection of local production,
or of the local exposure to these peptides, but only of the
degree of degradation subsequent to their action. In
resent in BCF. particular it should be considered whether differences in
IF is ['25I]met- peptide concentrations between type 1 and type 2 BCF could
as ACE is a be due to differences in levels of peptidases between the two
nstrated that types of fluid, such as that reported here for ACE.
)eak from the
revious report
rboxypeptidase Location of the peptidases
s and convert The data presented here do not allow the origin of these
deed a small peptidases to be determined. They could derive from
re 3b and this epithelial cells, stromal cells or by uptake from the
rl., 1986). This circulation, although the last possibility seems unlikely for
enkephalinase, ACE as serum ACE levels were inversely correlated with
r ['25I]Tyr-Gly- BCF levels. The origins of other components of BCF are also
as inhibited by unknown. The ACE activity was also detected in the
ch are specific circulation, suggesting that it may be in the soluble form,
which is known to occur in the circulation (Varela and Saez,
ICF using the 1993). As enkephalinase was detected in the cyst fluid it is
rnd was also possible that this is also in a soluble form. Enkephalinase is
two different normally a membrane-bound enzyme, however a soluble
ild be expected form has been reported in blood and CSF (Spillantini et al.,
iCE inhibitors, 1990) and in urine (Aviv et al., 1995). If both growth factors
.ctivity is ACE. and enzymes are diffusible then it is possible for them to be
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derived from other areas of the breast and for them to
interact both in BCF and in other locations in the breast.
Peptidases and peptide grow-th factors
Enkephalinase levels are decreased. compared with normal
tissue. in endometrial (Pekonen et al., 1995). lung (Shipp et
al.. 1991; Ganju et al.. 1994) and breast (Gusterson et al..
1986) cancer. As enkephalinase hydrolyses gastrin-releasimg
peptide (GRP) and its amphibian counterpart bombesin
(Shipp et al., 1991) and as GRP and bombesin are potent
growth-promoting factors for a wide variety of cancers
(reviewed in Schrey and Patel, 1994) it seems possible that
a reduction of enkephalinase expression by cancer cells is
necessary for GRP to have a mitogenic effect. Indeed the
growth of bombesin-dependent small-cell lung carcinomas is
stimulated by enkephalinase inhibitors and reduced by
exogenous enkephalinase (Shipp et al., 1991).
GRP is present in BCF (Weber et al., 1989) and is present
in higher levels in type 1 fluids, leading to the suggestion that
it is a factor in the increased risk associated with type 1 BCF
(Lai et al. 1990a). If enkephalinase action in BCF. and in the
breast environment in general, is protective against the
mitogenic actions of GRP then it might be expected that
enkephalinase levels would be lower in type 1 BCF which is
associated with an increased risk of cancer, and higher in
type 2 fluids where there is no such association. This
possibility is currently being investigated. Although this
discussion has concentrated on GRP because of its potent
growth-promoting effects. it is known that enkephalinase can
cleave several other peptides (Kenny,. 1993). including
mitogenic peptides found in BCF. For example enkephali-
nase can cleave calcitomnn gene-related peptide (CGRP)
(Katayama et al.. 1991). which is present in BCF and can
be mitogenic (Weber et al.. 1989). as well as opiate peptides.
such as met-enkephalin-Arg Phe. whose levels in BCF have
not yet been determined.
Similar arguments can be put forward for the involvement
of ACE in the link between GCD and breast cancer. Serum
ACE levels are decreased in patients with lung, breast and
gastrointestinal tumours (Schweisfurth et al.. 1985: Varela
and Saez, 1993). which may represent a decrease in a
protective effect. ACE is capable of cleaving many peptides
(Hooper. 1991) including some with mitogenic properties. for
example the widely distributed peptide bradykinin. which
stimulates tumour growth (Sethi & Rozengurt. 1991). The
higher levels of ACE in type 2 BCF support the idea that
ACE activity might have a protective effect in the
environment of the breast.
Future investigations could include localisation of the
origin of the BCF peptidases by immunocytochemistry and
determining the effect of inhibitors of these peptidases on
breast cancer cell lines. as has already been done for
enkephalinase inhibitors in lung cancer cell lines (Shipp et
al., 1991; Ganju et al., 1994). and determining the effect of
these inhibitors on tumour growth in in vivo models.
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